Sprycel

Ukratko

Sprycel, with the active ingredient Dasatinib, is a targeted therapy for Philadelphia chromosome-positive CML and ALL. It works by blocking cancer-causing proteins, helping to stop the growth of abnormal cells. The drug is taken orally and requires close monitoring due to its potential for serious side effects. Sprycel offers an effective treatment option for certain types of leukemia.